No Data
No Data
H.C. Wainwright Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Edward White maintains $InflaRx(IFRX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 30.5% and a tota
InflaRx Hosts R&D Event Highlighting the Promise of INF904
InflaRx N.V. (Nasdaq: IFRX) today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor, INF904.
InflaRx's Drug Shows Life-Saving Potential in COVID-19
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination With Other Immunomodulators
InflaRx N.V. (Nasdaq: IFRX) announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.
05-2024-InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination With Other Immunomodulators
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego.
InflaRx's Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights
No Data